{"id":"W4409785682","doi":"10.1182/blood.2024027873","title":"A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"Active Biotech; Regeneron Pharmaceuticals; BeiGene; Sanofi; Genentech; Celgene; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Neutropenia; Adverse effect; Internal medicine; Refractory (planetary science); Multiple myeloma; Febrile neutropenia; Gastroenterology; Phases of clinical research; Progressive disease; Surgery; Clinical trial; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002089225,0.001357756,0.001937998,0.0004329228,0.0004266617,0.0009570473,0.0007379295,0.00130961,0.005744461],"category_scores_gemma":[0.001269991,0.0006230429,0.001470576,0.0003589031,0.0008109717,0.0008740628,0.0003959351,0.002376284,0.0007984647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008407171,"about_ca_system_score_gemma":0.001464298,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007211434,"about_ca_topic_score_gemma":0.001723425,"domain_scores_codex":[0.9994215,0.0003278846,0.00002886954,0.00009502935,0.00004180639,0.00008503904],"domain_scores_gemma":[0.9992648,0.0001602945,0.0001659219,0.00006420838,0.00004911992,0.0002957057],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9530413,0.02040535,0.001594402,0.0002977565,0.0008723006,0.00006853175,0.00006146504,0.0004028572,0.005034021,0.0001139698,0.0009623947,0.01714575],"study_design_scores_gemma":[0.9316893,0.06536309,0.001642615,0.00001022927,0.0002239202,0.00003538644,0.00001052189,0.0002786892,0.0002890876,0.00007720733,0.0003713937,0.000008640475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923887,0.001211365,0.0004039544,0.0005359961,0.0002233204,0.003650374,0.0005533731,0.00005837412,0.0009745811],"genre_scores_gemma":[0.9873556,0.001042434,0.001744472,0.001252252,0.0003353183,0.005053992,0.001068905,0.0000203233,0.002126625],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005744461,"threshold_uncertainty_score":0.01921713,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02022512990478543,"score_gpt":0.3084402270575456,"score_spread":0.2882150971527602,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}